KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
Experimental & Molecular Medicine
;
: 502-508, 2006.
Artigo
em Inglês
| WPRIM
| ID: wpr-181049
ABSTRACT
Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Benzopiranos
/
Movimento Celular
/
Células Cultivadas
/
Fator 2 de Crescimento de Fibroblastos
/
Neovascularização Fisiológica
/
Metaloproteinase 2 da Matriz
/
Inibidores da Angiogênese
/
Receptor 2 de Fatores de Crescimento do Endotélio Vascular
/
Células Endoteliais
/
Receptor Tipo 2 de Fator de Crescimento de Fibroblastos
Tipo de estudo:
Estudo prognóstico
Limite:
Animais
Idioma:
Inglês
Revista:
Experimental & Molecular Medicine
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS